Stock Pick

Author: therawinformant

  • Despite growing ad boycott, Facebook is too big for many advertisers to ignore

    Despite growing ad boycott, Facebook is too big for many advertisers to ignoreDespite a growing advertising boycott, many companies can't ignore Facebook.

    from Yahoo Finance https://ift.tt/2YPdCUs

  • Coronavirus update: Pfizer spurs new hope in vaccine race as NYC pulls back on dining plans

    Coronavirus update: Pfizer spurs new hope in vaccine race as NYC pulls back on dining plansPfizer (PFE) on Wednesday announced early positive results for the first phase of its coronavirus vaccine trial, sparking hopes that an effective treatment can help turn the tide amid an implacable surge in new infections.

    from Yahoo Finance https://ift.tt/2NHqHZI

  • If You Own 3M Co (MMM) Stock, Should You Sell It Now?

    If You Own 3M Co (MMM) Stock, Should You Sell It Now?If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on 3M Company (NYSE:MMM) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […]

    from Yahoo Finance https://ift.tt/2ZsRn5H

  • Facebook may be headed to the ‘graveyard of dinosaurs’: former Unilever CEO

    Facebook may be headed to the 'graveyard of dinosaurs': former Unilever CEOImagine co-founder and former long-time Unilever CEO Paul Polman speaks out on Facebook's recent actions.

    from Yahoo Finance https://ift.tt/2NIOxUZ

  • Here’s Why We’re Not Too Worried About Microbot Medical’s (NASDAQ:MBOT) Cash Burn Situation

    Here's Why We're Not Too Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although…

    from Yahoo Finance https://ift.tt/2BQIniN

  • Amgen defeats Novartis appeal over arthritis drug Enbrel’s patents

    from Yahoo Finance https://ift.tt/2YQd9l6

  • Virus Shot From Pfizer, BioNtech Shows Promise in Early Test

    Virus Shot From Pfizer, BioNtech Shows Promise in Early Test(Bloomberg) — An early trial of an experimental coronavirus vaccine from Pfizer Inc. and BioNtech SE showed it’s safe and prompted patients to produce antibodies against the new virus, keeping it in the lead pack for a pandemic shot.The messenger RNA product was tested on 45 healthy adults divided in several groups: 24 of them got two injections with two different doses of the experimental vaccine, 12 of them received a single shot with a very high dose and nine patients got two dummy injections. The two-shot groups produced the highest level of antibodies.Pfizer and Germany’s BioNTech are in a race with companies including AstraZeneca Plc, Moderna Inc. and dozens of other biopharmaceutical outfits and academic groups to come up with a safe and effective vaccine against Covid-19. With almost 10.5 million confirmed cases around the globe and over half a million deaths, drugmakers are under increasing pressure to deliver.“I see this as the first good news we’ve seen from Operation Warp Speed,” said Peter Hotez, a vaccine researcher and dean of the National School of Tropical Medicine at Baylor College of Medicine. Operation Warp Speed is a Trump administration program to bring a vaccine to market as quickly as possible.While it took two shots, the vaccine produced “significant levels of virus neutralizing antibody,” Hotez said.Pfizer shares gained as much as 5.6% on Wednesday in New York, while BioNtech shares jumped by as much as 19% in Germany.On Monday, shares of Inovio Pharmaceuticals Inc. slumped after the company released promising results on an experimental vaccine without giving enough detailed data.The study of Pfizer’s and BioNtech’s vaccine candidate, called BNT162b1, is undergoing scientific peer review, the partners said.The companies are evaluating at least four experimental vaccines at various doses and will pick the most promising one to move into the next stage of tests, which may start as early as this month and involve as many as 30,000 patients.If the vaccine is successful, the companies expect to manufacture up to 100 million doses by the end of this year and potentially more than 1.2 billion doses by the end of 2021. They would jointly to distribute the product worldwide except in China, where BioNTech has a collaboration with Fosun Pharma.There were no severe side effects in the study. Some patients had pain at the injection site and a low-grade fever after the second injection. One of the patients who got the single high dose experienced severe pain where he received the shot.(Updates with comment from medical expert in fourth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/2VRJ8PZ

  • Markets open higher on positive Pfizer vaccine data

    Markets open higher on positive Pfizer vaccine dataYahoo Finance’s Brian Sozzi and Jared Blikre break down today’s market action with Belpointe Chief Strategist David Nelson.

    from Yahoo Finance https://ift.tt/3ioAa6q

  • Illumina Sets Up In Shallow Base

    Illumina Sets Up In Shallow BaseIllumina is nearing a 377.90 flat-base buy point. The genomics sequencing machine giant previously broke out from a deep base, either a cup or wild, long double-bottom. Very deep, loose bases are less likely to work. Might want to wait to see if it sets up again in a more-bullish pattern.

    from Yahoo Finance https://ift.tt/38m6HW6

  • Boeing 737 MAX report may boost effort to reform U.S. airplane certification

    Boeing 737 MAX report may boost effort to reform U.S. airplane certificationA new report into the Federal Aviation Administration’s decision to certify the Boeing 737 MAX may help proponents seeking reforms to the long-standing practice of delegating some aircraft certification tasks to manufacturers. On Wednesday, the Transportation Department’s inspector general released a 52-page report that said Boeing withheld key information about a crucial safety system known as MCAS, that is tied to two fatal crashes and raises questions about whether Boeing employees performing work for the FAA faced undue pressure. On June 16, Senate Commerce Committee chairman Roger Wicker and the top Democrat on the panel Maria Cantwell introduced legislation to strengthen FAA oversight of aircraft certification.

    from Yahoo Finance https://ift.tt/2BVtgoe